Privi Speciality Chemicals Limited — PPTs, 05-08-2025: Investor Presentation

Here's a summary of the attached file, structured as requested:

**Financial Highlights:**

Q1 FY26 saw robust growth: standalone revenue up 29.6%, consolidated 21.7%. EBITDA surged 50.4% standalone and 45.3% consolidated. Profit After Tax (PAT) jumped 113.3% standalone and 97.1% consolidated, with improved margins across the board. ROCE and ROE also significantly increased. (Note: Prigiv's losses reduced consolidated profit).

**Strategic Initiatives & Growth Drivers:**

Phase 2 of the speciality aroma chemical project is progressing. Capacity augmentation (Phase 1 partly done, impacting Q2 FY26 onwards; fully by Q4 FY26 for FY27 growth) is key. Operational excellence initiatives are enhancing margins and capital returns.

**Business Developments:**

A proposed amalgamation of Privi Fine Sciences and Privi Biotechnology with Privi Speciality Chemicals aims to unlock synergies, boost efficiencies, and unify the structure for scalable growth.

**Market Position & Competitive Advantage:**

Strong demand across all products reinforces the company's position as a trusted partner. Privi achieved EcoVadis Platinum for ESG, ranking top 1% globally. Advantages include high R&D, sticky customer relationships, and high industry entry barriers.

**Investor Implications:**

Solid Q1 financials, strategic consolidation, and capacity expansion signal positive growth potential. Operational efficiencies and a strong market position could support sustained profitability for investors.